JNJ-61803534
JNJ-61803534 is a potent and orally active RORγt inverse agonist with an IC50 of 9.6 nM. JNJ-61803534 has anti-inflammatory activity. JNJ-61803534 inhibits IL-17A production in human CD4+ T cells under Th17 differentiation conditions[1].
Product Specifications
CAS Number
1917306-14-9
UNSPSC
12352005
Target
ROR
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/jnj-61803534.html
Concentration
10mM
Purity
99.84
Solubility
DMSO : 300 mg/mL (ultrasonic)
Smiles
O=C(C1=NC(C(N2[C@H](C)CCC2)=O)=C(C3=CC=C(C(C(F)(F)F)(O)C(F)(F)F)C(Cl)=C3Cl)S1)NCC(C)(O)C
Molecular Formula
C23H23Cl2F6N3O4S
Molecular Weight
622.41
References & Citations
[1]Xue X, et al. Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534. Sci Rep. 2021 May 26;11 (1) :11066.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
RORγ
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Complement C4d (C4D204), CF405S conjugate, 0.1mg/mL
Ep-CAM / CD326 (VU-1D9), CF740 conjugate, 0.1mg/mL
TNF alpha (J2D10), CF568 conjugate, 0.1mg/mL
